{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"199000","upperLimit":"266000","value":"232500"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Mean serum TRC105 concentrations were assessed at cycle 1 and cycle 2 on day 1, 8, 15, and 22 and on day 1 of every subsequent cycle using validated methods in order to determine the Cmax of TRC105","dispersionType":"Full Range","groups":[{"description":"All subjects will begin by receiving single agent TRC105 weekly. In the case of a complete response to single agent TRC105, subjects will continue to receive single agent TRC105 for at least 3 months following complete response. In the case of a partial response (without a complete response) to single agent TRC105, bevacizumab every two weeks will be added. In the absence of a partial or complete response to single agent TRC105, subjects will receive single agent bevacizumab every two weeks. In the absence of a complete response to single agent bevacizumab, or for subjects who have documented disease progression on a prior bevacizumab containing regimen, subjects will receive TRC105 weekly and bevacizumab every two weeks.\n\nTRC105: Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.\n\nBevacizumab: Bevacizumab will be dosed every two weeks.","id":"OG000","title":"TRC105 and/or Bevacizumab"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"cycle 2 day 1 (28 days after initiation of dosing)","title":"Maximum Plasma Concentration (Cmax) of TRC105.","type":"SECONDARY","unitOfMeasure":"ng/mL"}